Insider Tip: Biodelivery Sciences Chairman Owns Accentia Biopharmaceutical

Biodelivery Sciences International (BDSI) announced Wednesay that they received a commercial partnership for their Bema Fetanyl drug candidate with Meda AB, which could add up to $90 million in payments for BDSI. This proves very rewarding for shareholders of BDSI, including the Chairman, Dr. Frank O'Donnel, who purchased 400,000 shares last January $2.68.00 per share, along with an additional 400,000 at $2.68, shares though his 100% owned VC firm Hopkins Capital Group.

Recently, Dr. O'Donnel purchased 875,000 shares of Accentia Biopharmaceuticals (ABPI) at $8.87.00 per share. The current market price is $2.20.00. Accentia Biopharmaceuticals recently provided interim blinded data on the ongoing clinical trial of Sinunase which showed that 50% of the people in the trial are responding positively.

We just don't know if it's the drug or the placebo. From what I understand, in order to participate in the trial one had to have failed surgery, antibiotics, and two weeks of saline irrigation. It is a 50/50 trial in which half are getting the drug and the other half a placebo. If they prove it works it will be a windfall for Accentia shareholders with a potential market of over $2 billion dollars. Dr. O'Donnel purchased the shares recently at a 400% premium to the current market price.

Comments

[Billy Staples:]

It is about time in my opinion that the Hopkins group in a non direct way, even though of all the acquisition's it has, Accentia is the one started, built and designed by the Hopkins Group themselves. to see also the need for another quick form of Fentanyl realized other than the 'lollipop' is well needed and not so well documented or I believe known outside of the companies involved, want to be involves or certain people who I know are long awaiting for alternative forms of Fentanyl infusion into the body, either really quick or real moderate. The FDA recently having problems with 2 or 3 of the reservoir type patches, leaving only one type generic left. Which too me and I am in the 50% on this don't believe it'd effectiveness equals the reservoir type, which is still not that wonderful.

this is an exciting mixture of drugs, companies, brilliance and expertise and to see what comes out of it should be interesting

Staples


check out the website for a different view, sort of!

2008 Aug 18 10:31 AM

[knowledgebanc:]

BDSI is a buy... Aug. 29 will validate my assumptions.


On Aug 18 10:31 AM mr. ouch wrote:

> It is about time in my opinion that the Hopkins group in a non direct
> way, even though of all the acquisition's it has, Accentia is the
> one started, built and designed by the Hopkins Group themselves.
> to see also the need for another quick form of Fentanyl realized
> other than the 'lollipop' is well needed and not so well documented
> or I believe known outside of the companies involved, want to be
> involves or certain people who I know are long awaiting for alternative
> forms of Fentanyl infusion into the body, either really quick or
> real moderate. The FDA recently having problems with 2 or 3 of the
> reservoir type patches, leaving only one type generic left. Which
> too me and I am in the 50% on this don't believe it'd effectiveness
> equals the reservoir type, which is still not that wonderful.
>
>
> this is an exciting mixture of drugs, companies, brilliance and expertise
> and to see what comes out of it should be interesting
>
> Staples
>
>
> check out the website for a different view, sort of!

2008 Aug 24 12:52 AM